NMI TT Pharmaservices establishes new branch in Berlin
![](/46/pdcnewsitem/03/62/56/nmi%20tt.jpg)
The new outstation will provide life science researchers with the company's proprietary DigiWest multiplex protein profiling services, to accelerate lead characterisation, disease mechanism and drug mode-of-action analyses, as well as biomarker identification projects for industrial clients and academic partners.
NMI TT Pharmaservices, a non-clinical contract research provider based in Reutlingen/Germany, is growing its operations by establishing a new branch at the Bayer HealthCare CoLaborator in Berlin.
The new outstation is located on the Bayer HealthCare campus, within the CoLaborator building that is rented out by Bayer to smaller companies and start-ups. NMI TT Pharmaservices will be using the new and already functional laboratory space to provide life science researchers with its proprietary DigiWest multiplex protein profiling services, to accelerate lead characterisation, disease mechanism and drug mode-of-action analyses, as well as biomarker identification projects for industrial clients and academic partners alike. In addition, the new office will play a key role for advancing NMI TT Pharmaservices’ market positioning by expanding its business activities beyond the existing well-established customer base.
“We are very excited to start this new phase in our company’s development,” commented Prof. Dr Hugo Hämmerle, CEO of NMI TT GmbH. “We see our expansion to Berlin as a unique opportunity to intensify our business development efforts across the international pharma and biotech market. This move also happens at a particularly promising time in the development of the proteomics field, which we are keen to help drive forward in the years to come, now through both our Reutlingen team and our new Berlin unit.”
“The chances of this new endeavour are manifold,” added Dr Christoph Sachse, Site Head of the NMI TT Berlin operation. “We expect that being closer to the needs of pharma R&D scientists and the lively Berlin biotech community will substantially help us in further developing and in marketing our wide range of contract research offerings, in particular our multiplex protein profiling platform, but also our capabilities in cellular assays and in generating customised cell lines.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance